ABSTRACT
We reported a cumulative incidence of hypertension of 28% among individuals successfully treated for pulmonary tuberculosis (TB) with no prior hypertension indication at TB treatment initiation (i.e., prevalent hypertension). The cumulative incidence of hypertension among those with ≥1 cavitary lesion was twice the cumulative incidence among those without cavitary lesions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by grants from the National Institutes of Health (NIH) including the National Institute of Allergy and Infectious Diseases (NIAID) [R03AI133172 to MJM, R03AI139871 to RRK, R01AI153152 to MJM], the National Heart, Lung, and Blood Institute (NHLBI) [R01HL156779 to MAH], and the Fogarty International Center (FIC) [R21TW011157 to MK and MJM]. ADS was supported by a Vanderbilt Emory Cornell Duke (VECD) Global Health Fellowship, funded by the NIH FIC (D43TW009337). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was submitted to, reviewed, and approved by the Institutional Review Boards (IRBs) at Emory University, Atlanta, USA, and the ethics committee at the National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia (FWA000020831).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
The data that support the findings of this study are available from the corresponding author, ADS, upon reasonable request.
